Jennifer K McGee-Avila

Dr. Jennifer K McGee-Avila

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JMJennifer K McGee-Avila
Jennifer K McGee-Avila
GSGita Suneja
Gita Suneja
EEEric A. Engels
Eric A. Engels
ARAnne F. Rositch
Anne F. Rositch
MHMarie-Josephe Horner
Marie-Josephe Horner
Jessica IslamJessica Islam
Jessica Islam
PURPOSE: People with HIV (PWH) have worse cancer outcomes, partially because of inequities in cancer treatment. We evaluated cancer treatment disparities among PWH, including an assessment of changes in disparities over time.METHODS: We used data from the HIV/AIDS Cancer Match Study, a population-based HIV and cancer registry linkage to examine diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and cancers of the cervix, lung, anus, prostate, colon, and female breast. Outcomes included receipt of (1) any cancer treatment and (2) standard therapy among patients with local-stage cancer. We assessed associations between HIV and each outcome by estimating adjusted prevalence odds ratios (aORs) with 95% CI and trends over time. We identified predictors of nonreceipt of cancer treatment in PWH.RESULTS: From 2001 to 2019, compared with people with cancer without HIV (n = 2,880,955), PWH (n = 16,334) were more likely to not receive cancer treatment for cervical cancer (aOR, 2.03 [95% CI, 1.52 to 2.70]), DLBCL (aOR, 1.53 [95% CI, 1.38 to 1.70]), HL (aOR, 1.39 [95% CI, 1.19 to 1.63]), lung cancer (aOR, 1.79 [95% CI, 1.65 to 1.93]), prostate cancer (aOR, 1.32 [95% CI, 1.21 to 1.44]), colon cancer (aOR, 1.73 [95% CI, 1.43 to 2.08]), and breast cancer (aOR, 1.38 [95% CI, 1.07 to 1.77]). Similar associations were observed in PWH with local-stage cancers although no difference was observed for anal cancers. The association between HIV and nonreceipt of cancer treatment significantly decreased over time for breast, colon, and prostate cancers (all P trend <.0001), but PWH remained less likely to receive treatment in 2014-2019 for DLBCL, cervix, and lung cancers. Among PWH, Black individuals, people who inject drugs, and those 65 years and older were less likely to receive cancer treatment.CONCLUSION: Disparities in receipt of cancer treatment persist for PWH in the United States in contemporary time periods. Solutions to address inequitable receipt of cancer treatment among PWH are urgently needed.

23 August 2023 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
JMJennifer K McGee-Avila
Jennifer K McGee-Avila
IAIlona Argirion
Ilona Argirion
EEEric A Engels
Eric A Engels
TOThomas R O’brien
Thomas R O’brien
MHMarie-Josèphe Horner
Marie-Josèphe Horner
MSMeredith S Shiels
Meredith S Shiels
People with HIV have higher risk of hepatocellular carcinoma than the general population, partly because of higher prevalence of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV). We calculated standardized incidence ratios for hepatocellular carcinoma in people with HIV by comparing rates from people with HIV in the HIV/AIDS Cancer Match Study, a population-based HIV and cancer registry linkage, to those in the general population. We used multivariable Poisson regression to estimate adjusted incidence rate ratios among people with HIV and linked the Texas HIV registry with medical claims data to estimate adjusted odds ratios (AORs) of HBV and HCV in hepatocellular carcinoma patients with logistic regression. Compared with the general population, hepatocellular carcinoma rates in people with HIV were elevated 2.79-fold (n = 1736; 95% confidence interval [CI] = 2.66 to 2.92). Hepatocellular carcinoma rates decreased statistically significantly from 2001-2004 to 2015-2019 (P < .001). Compared with men who have sex with men, hepatocellular carcinoma risk was elevated 4.28-fold among men who injected drugs (95% CI = 3.72 to 4.93) and 1.83-fold among women who injected drugs (95% CI = 1.49 to 2.26). In Texas, 146 hepatocellular carcinoma cases among people with HIV were linked to claims data: 25% HBV positive, 59% HCV positive, and 13% coinfected with HBV and HCV. Compared with men who had sex with men, people who inject drugs had 82% decreased odds of HBV (AOR = 0.18, 95% CI = 0.05 to 0.63) and 2 times the odds of HCV (AOR = 20.4, 95% CI = 3.32 to 125.3). During 2001-2019, hepatocellular carcinoma risk declined among people with HIV, though rates remain statistically significantly elevated compared with the general population, particularly among people who inject drugs. Prevention and treatment of HBV/HCV are needed to reduce hepatocellular carcinoma risk among people with HIV.

19 May 2023 in Health Services Research
Verified
Journal Article
Open access
JMJennifer K McGee-Avila
Jennifer K McGee-Avila
JRJennifer Richmond
Jennifer Richmond
KHKevin A. Henry
Kevin A. Henry
ASAntoinette M. Stroup
Antoinette M. Stroup
JTJennifer Tsui
Jennifer Tsui
Objective: To examine geospatial patterns of cancer care utilization across diverse populations in New Jersey—a state where most residents live in urban areas.Data Sources/Study Setting: We used data from the New Jersey State Cancer Registry from 2012 to 2014.Study Design: We examined the location of cancer treatment among patients 20–65 years of age diagnosed with breast, colorectal, or invasive cervical cancer and investigated differences in geospatial patterns of care by individual and area‐level (e.g., census tract‐level) characteristics.Data Collection/Extraction Methods: Multivariate generalized estimating equation models were used to determine factors associated with receiving cancer treatment within residential counties, residential hospital service areas, and in‐state (versus out‐of‐state) care.Principal Findings: We observed significant differences in geospatial patterns of cancer treatment by race/ethnicity, insurance type, and area‐level factors. Even after adjusting for tumor characteristics, insurance type, and other demographic factors, non‐Hispanic Black patients had a 5.6% higher likelihood of receiving care within their own residential county compared to non‐Hispanic White patients (95% CI: 2.80–8.41). Patients insured with Medicaid and those without insurance had higher likelihoods of receiving care within their residential county compared to privately insured individuals. Patients living in census tracts with the highest quintile of social vulnerability were 4.6% more likely to receive treatment within their residential county (95% CI: 0.00–9.30) and were 2.7% less likely to seek out‐of‐state care (95% CI: −4.85 to −0.61).Conclusions: Urban populations are not homogenous in their geospatial patterns of cancer care utilization, and individuals living in areas with greater social vulnerability may have limited opportunities to access care outside of their immediate residential county. Geographically tailored efforts, along with socioculturally tailored efforts, are needed to help improve equity in cancer care access.

1 January 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
MDMichelle Doose
Michelle Doose
DVDana Verhoeven
Dana Verhoeven
JSJaneth I. Sanchez
Janeth I. Sanchez
JMJennifer K McGee-Avila
Jennifer K McGee-Avila
VCVeronica Chollette
Veronica Chollette
SWSallie J. Weaver
Sallie J. Weaver
PURPOSE: Sixty percent of adults have multiple chronic conditions at cancer diagnosis. These patients may require a multidisciplinary clinical team-of-teams, or a multiteam system (MTS), of high-complexity involving multiple specialists and primary care, who, ideally, coordinate clinical responsibilities, share information, and align clinical decisions to ensure comprehensive care needs are managed. However, insights examining MTS composition and complexity among individuals with cancer and comorbidities at diagnosis using US population-level data are limited. METHODS: Using SEER-Medicare data (2006-2016), we identified newly diagnosed patients with breast, colorectal, or lung cancer who had a codiagnosis of cardiopulmonary disease and/or diabetes (n = 75,201). Zaccaro's theory-based classification of MTSs was used to categorize clinical MTS complexity in the 4 months following cancer diagnosis: high-complexity (≥ 4 clinicians from ≥ 2 specialties) and low-complexity (1-3 clinicians from 1-2 specialties). We describe the proportions of patients with different MTS compositions and quantify the incidence of high-complexity MTS care by patient groups. RESULTS: The most common MTS composition was oncology with primary care (37%). Half (50.3%) received high-complexity MTS care. The incidence of high-complexity MTS care for non-Hispanic Black and Hispanic patients with cancer was 6.7% (95% CI, −8.0 to −5.3) and 4.7% (95% CI, −6.3 to −3.0) lower than non-Hispanic White patients with cancer; 13.1% (95% CI, −14.1 to −12.2) lower for rural residents compared with urban; 10.4% (95% CI, −11.2 to −9.5) lower for dual Medicaid-Medicare beneficiaries compared with Medicare-only; and 16.6% (95% CI, −17.5 to −15.8) lower for colorectal compared with breast cancer. CONCLUSION: Incidence differences of high-complexity MTS care were observed among cancer patients with multiple chronic conditions from underserved populations. The results highlight the need to further understand the effects of and mechanisms through which care team composition, complexity, and functioning affect care quality and outcomes.

1 September 2019 in Journal for Healthcare Quality
Verified
Journal Article
Closed access
MDMichelle Doose
Michelle Doose
JMJennifer K McGee-Avila
Jennifer K McGee-Avila
ASAntoinette M. Stroup
Antoinette M. Stroup
JFJeanne Ferrante
Jeanne Ferrante
BXBaichen Xu
Baichen Xu
JTJennifer Tsui
Jennifer Tsui
There is growing evidence that shared care, where the oncologist, primary care physician, and/or other specialty physicians jointly participate in care, can improve the quality of patients' cancer care. This cross-sectional study of breast and colorectal cancer patients (N = 534) recruited from the New Jersey State Cancer Registry examined patient and health system factors associated with receipt of shared care during cancer treatment into the early survivorship phase. We also assessed whether shared care was associated with quality indicators of cancer care: receipt of comprehensive care, follow-up care instructions, and written treatment summaries. Less than two-thirds of participants reported shared care during their cancer treatment. The odds of reporting shared care were 2.5 (95% CI: 1.46–4.17) times higher for colorectal than breast cancer patients and 52% (95% CI: 0.24–0.95) lower for uninsured compared with privately insured, after adjusting for other sociodemographic, clinical/tumor, and health system factors. No significant relationships were observed between shared care and quality indicators of cancer care. Given a substantial proportion of patients did not receive shared care, there may be missed opportunities for integrating primary care and nononcology specialists in cancer care, who can play critical roles in care coordination and managing comorbidities during cancer treatment.

7 November 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
QLQianlai Luo
Qianlai Luo
MHMarie-Josèphe Horner
Marie-Josèphe Horner
CHCameron Brady Haas
Cameron Brady Haas
JMJennifer K McGee-Avila
Jennifer K McGee-Avila
RPRuth M Pfeiffer
Ruth M Pfeiffer
MSMeredith S Shiels
Meredith S Shiels
Background: It is unclear whether cancer risk among people with human immunodeficiency virus (HIV, PWH) has declined equally across all racial/ethnic and transmission risk groups. Methods: We used data on PWH aged ≥20 years from the HIV/AIDS Cancer Match Study during 2001–2019. We used Poisson regression to assess time trends in incidence rates for each cancer site by racial/ethnicity and risk groups, adjusting for age, registry, and sex. We also estimated adjusted rate ratios across racial and ethnic and risk groups in 2001–2004 and 2015–2019. Results: Trends in age-standardized rates differed across racial/ethnic groups and across risk groups for some cancers. For example, liver cancer rates declined 23% per 5-year period among White PWH, 11% among Black PWH, and 18% among Hispanic PWH. Anal cancer rates declined among men who have sex with men, were stable among people who inject drugs, and increased among other risk groups. Between 2001–2004 and 2015–2019, the relative difference in cancer incidence rates by race/ethnicity increased for Hodgkin lymphoma (HL) and liver cancer but decreased for non-Hodgkin lymphoma (NHL); by risk group, relative differences increased for NHL and liver cancer and decreased for HL and lung and anal cancers. Conclusions: Among PWH in the United States during 2001–2019, HL, lung, liver, and cervical cancer rate trends were different across racial/ethnic groups. HL, lung, anal, and liver cancer rate trends were different across risk groups. Future work should examine underlying causes of the differences in trends.